Walle T, Conradi E C, Walle U K, Fagan T C, Gaffney T E
Clin Pharmacol Ther. 1979 Dec;26(6):686-95. doi: 10.1002/cpt1979266686.
The comparative disposition of propranolol glucuronide (PG) and propranolol was determined in 35 patients with hypertension or coronary artery disease during initiation of propranolol therapy, during steady-state conditions, and after discontinuation of propranolol (dose range, 40 to 960 mg daily, every 6 hr). The 2.3-fold PG cumulation in plasma was identical to propranolol cumulation. PG plasma levels were about 4 times as high as propranolol levels over the whole dose range. Unexpectedly slow terminal elimination rate of propranolol (t1/2 approximately 16 to 24 hr) on discontinuation of propranolol appeared to be related to equally slow PG elimination. PG and propranolol could be detected in plasma and urine up to 3 to 5 days after propranolol discontinuation. The PG formed in man was deconjugated to propranolol in the dog after intravenous administration, suggesting that PG may serve as a storage pool for propranolol. Observations consistent with systemic and enteric deconjugation of PG, including enterohepatic recirculation, may, at least in part, explain the observed propranolol cumulation as well as the slow elimination of propranolol after its discontinuation. PG renal clearance (29 to 70 ml/min) and PG plasma levels were highly dependent on glomerular filtration rate, suggesting that PG may cumulate abnormally in patients with severe renal disease.
在35例高血压或冠心病患者中,在普萘洛尔治疗开始时、稳态条件下以及普萘洛尔停药后(剂量范围为每日40至960 mg,每6小时一次),测定了普萘洛尔葡萄糖醛酸苷(PG)和普萘洛尔的比较处置情况。血浆中PG的2.3倍累积与普萘洛尔的累积相同。在整个剂量范围内,PG血浆水平约为普萘洛尔水平的4倍。普萘洛尔停药后,其意外缓慢的终末消除率(t1/2约为16至24小时)似乎与同样缓慢的PG消除有关。普萘洛尔停药后3至5天,血浆和尿液中均可检测到PG和普萘洛尔。静脉注射后,人体内形成的PG在犬体内可去结合为普萘洛尔,提示PG可能作为普萘洛尔的储存库。与PG的全身和肠道去结合一致的观察结果,包括肠肝循环,可能至少部分解释了观察到的普萘洛尔累积以及普萘洛尔停药后消除缓慢的现象。PG的肾清除率(29至70 ml/min)和PG血浆水平高度依赖于肾小球滤过率,提示PG在严重肾病患者中可能异常累积。